Ovid Therapeutics Announces Participation in Two Upcoming Investors Conferences
New York, NY – September 1, 2016 – (Business Wire) – Ovid Therapeutics, Inc., a privately held biopharmaceutical company focused on developing therapies for orphan diseases of the brain, today announced its participation in two upcoming investor conferences:
- Citi 11th Annual Biotech Conference. Members of the company’s management team will participate in one-on-one meetings on Wednesday, September 7, 2016, at the Mandarin Oriental Hotel in Boston.
- Baird Global Healthcare Conference. Yaron Werber, M.D., chief business and financial officer of Ovid, will present on Thursday, September 8, 2016, at 9:40 a.m. ET at the New York Palace in New York City.
About Ovid Therapeutics, Inc.
Ovid Therapeutics, Inc. is a privately held, New York-based, biopharmaceutical company committed to transforming the lives of patients with orphan diseases of the brain. Ovid focuses on patients and their unmet medical needs. Using the significant operational, product development and business development experience of its management team, Ovid aims to become a leading neurology company, with multiple products and a rich pipeline, coupled with compelling research and development. Ovid has raised $80M in substantially oversubscribed financings led by Fidelity Management and Research Company and including Cowen Private Investments, Sanofi-Genzyme BioVentures, Tekla Capital Management, Sphera Global Healthcare Fund, Jennison Associates, Redmile Group, DoubleLine Equity Healthcare Fund, and Cormorant Asset Management, as well as additional blue chip mutual funds and leading life sciences investors.
For more information on Ovid, please visit http://ovidrx.com.